Literature DB >> 15947307

The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature.

Don D Sin1, LieLing Wu, S F Paul Man.   

Abstract

STUDY
OBJECTIVES: Conditions that give rise to reduced lung function are frequently associated with low-grade systemic inflammation, which may lead to poor cardiovascular outcomes. We sought to determine the relationship between reduced FEV1 and cardiovascular mortality, independent of smoking.
DESIGN: Longitudinal population-based study and a meta-analysis of literature.
SETTING: Representative sample of the general population. PARTICIPANTS: Participants of the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study who were 40 to 60 years of age at baseline assessment (n = 1,861). MEASUREMENTS AND
RESULTS: We compared the risk of cardiovascular mortality across quintiles of FEV1. Individuals in the lowest FEV1 quintile had the highest risk of cardiovascular mortality (relative risk [RR], 3.36; 95% confidence interval [CI], 1.54 to 7.34). Compared to FEV1 quintile 1, individuals in quintile 5 had a fivefold increase in the risk of death from ischemic heart disease (RR, 5.65; 95% CI, 2.26 to 14.13). We also performed a systematic review of large cohort studies (> 500 participants) that reported on the relationship between FEV1 and cardiovascular mortality (12 studies; n = 83,880 participants). Compared to participants in the highest FEV1 category, those with reduced FEV1 had a higher risk of cardiovascular mortality (pooled RR, 1.77; 95% CI, 1.56 to 1.97).
CONCLUSIONS: There is strong epidemiologic evidence to indicate that reduced FEV1 is a marker for cardiovascular mortality independent of age, gender, and smoking history.

Entities:  

Mesh:

Year:  2005        PMID: 15947307     DOI: 10.1378/chest.127.6.1952

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  259 in total

Review 1.  Applied Healthspan engineering.

Authors:  James W Larrick; Andrew Mendelsohn
Journal:  Rejuvenation Res       Date:  2010 Apr-Jun       Impact factor: 4.663

2.  Decreased Lung Function and All-Cause Mortality in HIV-infected Individuals.

Authors:  Matthew R Gingo; Mehdi Nouraie; Cathy J Kessinger; Ruth M Greenblatt; Laurence Huang; Eric C Kleerup; Lawrence Kingsley; Deborah K McMahon; Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2018-02

3.  Vascular dysfunction and chronic obstructive pulmonary disease: the role of redox balance.

Authors:  Stephen J Ives; Ryan A Harris; Melissa A H Witman; Anette S Fjeldstad; Ryan S Garten; John McDaniel; D Walter Wray; Russell S Richardson
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

4.  Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal:  Eur J Heart Fail       Date:  2009-01-27       Impact factor: 15.534

5.  Predictors of cardiopulmonary hospitalization in chronic spinal cord injury.

Authors:  Anthony C Waddimba; Nitin B Jain; Kelly Stolzmann; David R Gagnon; James F Burgess; Lewis E Kazis; Eric Garshick
Journal:  Arch Phys Med Rehabil       Date:  2009-02       Impact factor: 3.966

Review 6.  Heart-lung interaction via infection.

Authors:  Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2014-01

Review 7.  Should mild COPD be treated? Evidence for early pharmacological intervention.

Authors:  Amany F Elbehairy; Katherine A Webb; J Alberto Neder; J Alberto Neder; Denis E O'Donnell
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546

8.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

Review 9.  Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.

Authors:  Vanessa M McDonald; Isabel Higgins; Peter G Gibson
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

Review 10.  Comorbidities in chronic obstructive pulmonary disease.

Authors:  Wissam M Chatila; Byron M Thomashow; Omar A Minai; Gerard J Criner; Barry J Make
Journal:  Proc Am Thorac Soc       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.